千亿市场群雄逐鹿，GLP-1领头雁华东医药司美格鲁肽国内上市申请获受理

Core Insights - Huadong Medicine's subsidiary, Jiangdong Company, received acceptance for the marketing application of Semaglutide injection for blood sugar control in adults with type 2 diabetes [1] - The clinical trial application for Semaglutide's weight management indication was approved in September 2024, with the Phase III trial completed in December 2024 [1] - Semaglutide is recognized for its significant market potential due to its effective blood sugar and weight management capabilities [2] Industry Overview - The global diabetes market is experiencing substantial growth, with the number of adults with diabetes increasing from approximately 200 million in 1990 to 828 million in 2022 [4] - In China, the number of adult diabetes patients reached about 148 million in 2022, accounting for 18% of the global total, with a high untreated rate of 52.7% [4] - The diabetes treatment market is expected to grow as clinical diagnosis and treatment rates improve [4] Company Developments - Huadong Medicine has a comprehensive pipeline of over 20 commercialized and in-development products targeting various diabetes treatment mechanisms, including GLP-1 receptor agonists [5] - The company’s Semaglutide injection demonstrated comparable efficacy and safety to Novo Nordisk's control drug in Phase III trials, with slightly lower adverse event rates [3] - Huadong Medicine is advancing multiple innovative products, including oral small molecule GLP-1 receptor agonists and dual-target agonists, with ongoing clinical trials [6][7] Market Position - Huadong Medicine is positioned as a strong competitor in the diabetes treatment sector, leveraging its extensive GLP-1 product pipeline and research capabilities [7] - The company aims to become a leading player in the GLP-1 market, capitalizing on its comprehensive product offerings and competitive advantages [7]